TICKERNERD
Menu
DNADNAHealthcare · Biotechnology

DNA Stock Forecast: Ginkgo Bioworks Holdings, Inc. Price Predictions for 2026-2027

Last close, 14 Sept 2026
$7.01
+3.85% on the day

The 3 Wall Street analysts covering Ginkgo Bioworks Holdings, Inc. hold a median 12-month price target of $7 — -0.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 12 Sept 2026 — in the lower half.

Market cap
$454.5M
Ticker Nerd rank
40 / 100
Median analyst target
$7.00
Analysts covering
3
Revenue$20.2M−59.4% y/y
Operating income−$58.5M
Net income−$46.7M
Free cash flow−$46.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.9%
1M
+3.2%
YTD
−15.6%
1Y
−30.0%
From 52W high
−56.6%
From 52W low
+27.9%
$5
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ginkgo Bioworks Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
40 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Issuance
60
Size
55
Revisions
52
Quality
52
Growth
37
Value
35
Volatility
21
Momentum
20

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (20): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4$6$8$10$12$14$16Oct 25Jan 26Apr 26Jul 26DNAHigh $9.00Median $7.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
0 Buy1 Hold2 Sell
Low $5.00Median $7.00High $9.00

The green dot is the last close — the median target sits −0.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Sept 2026BTIGReiteratesSell$5.00
7 Aug 2026TD CowenDowngradeHold$12 → $9.00
7 Aug 2026TD CowenDowngradeHold—
12 Mar 2026BTIGMaintainsSell$9.00 → $5.00
12 Mar 2026BTIGMaintainsSell—
8 Jan 2026TD CowenMaintainsBuy—
25 Aug 2025BTIGMaintainsSell—
20 Sept 2024TD CowenMaintainsBuy—
23 Aug 2024BTIGMaintainsSell—
9 July 2024Goldman SachsMaintainsSell—
26 June 2024BTIGMaintainsSell—
15 May 2024BTIGDowngradeSell—
15 May 2024Morgan StanleyMaintainsEqual-Weight—
10 May 2024William BlairDowngradeUnderperform—
1 Mar 2024TD CowenMaintainsOutperform—
23 Jan 2024Goldman SachsMaintainsSell—
22 Jan 2024Goldman SachsMaintainsSell—
15 Nov 2023Raymond JamesDowngradeMarket Perform—
14 Nov 2023Raymond JamesDowngradeMarket Perform—
9 Nov 2023BTIGDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DNA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DNA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Sept 2026, Ginkgo Bioworks Holdings, Inc. returned −30.0% against +17.5% for the S&P 500, dividends included.

DNA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Oct 25Jan 26Apr 26Jul 26DNAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Ginkgo Bioworks Holdings, Inc. (DNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
3.5×

Cheaper than 36% of US stocks

Price / book
1.0×

Cheaper than 72% of US stocks

EV / EBITDA
−2.1×

Cheaper than 72% of US stocks

Growth & margins
Revenue growth (YoY)
−48.5%

Higher than 6% of US stocks

Earnings growth (YoY)
−59.4%

Higher than 8% of US stocks

Gross margin
91.5%

Higher than 97% of US stocks

Operating margin
−285.0%

Higher than 9% of US stocks

Net margin
−219.6%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−59.9%

Higher than 19% of US stocks

Return on assets
−16.7%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ginkgo Bioworks Holdings, Inc. (DNA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ginkgo Bioworks Holdings, Inc. has a market value of $454.5M and an enterprise value of $556.5M.

  • Revenue in the twelve months to 30 June 2026: $111.9M. The latest quarter shrank 48.5% year on year.

  • Net income over the same four quarters: −$290.8M, a −260.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$174.8M.

  • Shares outstanding: 63.7M.

  • Trailing P/E: −1.2×; forward P/E: −2.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Ginkgo Bioworks Holdings, Inc. employs 485 people — $231K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

DNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DNAGinkgo Bioworks Holdings, Inc.$454.5M
40
KYTXKyverna Therapeutics, Inc.$438.8M
41
CCCCC4 Therapeutics, Inc.$431.8M
69
CABACabaletta Bio, Inc.$445.1M
27
AVIRAtea Pharmaceuticals, Inc.$425.9M
67
ARCTArcturus Therapeutics Holdings, Inc.$418.5M
66
EDITEditas Medicine, Inc.$414.3M
78

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ginkgo Bioworks Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DNA news & analysis

Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines

Business Wire · 10 Sept 2026positive

Ginkgo Bioworks announced it has been awarded a subcontract for up to $17.5 million under ARPA-H's Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. The company will serve as a subcontractor to prime contractor Waterfall Scientific on the ESCALATOR project, which aims to build an autonomous manufacturing system for individualized RNA medicines.

Why it matters — The award expands Ginkgo's involvement in advanced biomanufacturing for individualized RNA medicines, positioning the company within a prominent federal health research initiative.

Ginkgo Bioworks Q2 Earnings Call Highlights

MarketBeat · 8 Aug 2026negative

Ginkgo Bioworks reported second-quarter 2026 revenue of $20 million, down 48% year over year, as the company continued pivoting toward autonomous laboratory systems, contract research services, and related software. The figures were highlighted in its Q2 earnings call coverage.

Why it matters — The sharp revenue decline and ongoing strategic shift signal how Ginkgo is repositioning its business model, which is material for investors tracking the company's transition.

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published a transcript of Ginkgo Bioworks Holdings, Inc.'s Q2 2026 earnings call. The transcript covers the company's second-quarter results and management commentary.

Why it matters — A DNA watcher would use this transcript for the full detail of Ginkgo's Q2 2026 results and management's discussion.

FAQ

Frequently asked questions about DNA stock

What is the DNA stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Ginkgo Bioworks Holdings, Inc. have a median 12-month price target of $7, with estimates ranging from $5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DNA stock a buy right now?

Of the 3 analysts covering Ginkgo Bioworks Holdings, Inc., 0 rate it a Buy, 1 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Ginkgo Bioworks Holdings, Inc. 40 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DNA?

As at 12 Sept 2026, Ginkgo Bioworks Holdings, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will DNA stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies -0.1% from the last close, and Ticker Nerd's factor model ranks Ginkgo Bioworks Holdings, Inc. 40 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DNA stock forecast for 2030?

No analyst covering Ginkgo Bioworks Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $9 over the next 12 months.

How has DNA stock performed over the past year?

Ginkgo Bioworks Holdings, Inc. returned -30.0% over the 12 months to 14 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ginkgo Bioworks Holdings, Inc. do?

Ginkgo Bioworks Holdings, Inc. Class A Common Stock represents ownership in Ginkgo Bioworks Holdings, a biotechnology company focused on cell engineering and biological design.

What is the latest news on DNA?

The most recent item we track (Business Wire, 10 Sept 2026): "Ginkgo Bioworks Joins ARPA-H GIVE Program to Build Autonomous Manufacturing System for Individualized RNA Medicines". Ginkgo Bioworks announced it has been awarded a subcontract for up to $17.5 million under ARPA-H's Genetic Medicines and Individualized Manufacturing for Everyone (GIVE) program. The company will serve as a subcontractor to prime contractor Waterfall Scientific on the ESCALATOR project, which aims to build an autonomous manufacturing system for individualized RNA medicines.

Company

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. Class A Common Stock represents ownership in Ginkgo Bioworks Holdings, a biotechnology company focused on cell engineering and biological design. Ginkgo Bioworks develops a platform that helps customers design, build, and test custom microbes and other biological systems for use in industries such as pharmaceuticals, agriculture, food, industrial chemicals, and specialty materials. The company provides biological R&D services, automation-enabled laboratory tools, and data-driven software that support the research, development, and commercialization of engineered organisms. It also serves government and commercial clients through biosecurity-related offerings that support biological monitoring and surveillance. Headquartered in Boston, Massachusetts, Ginkgo Bioworks plays a specialized role in the life sciences market by supplying infrastructure and services that make biological engineering more accessible across multiple sectors.

CEO Dr. Jason Kelly Ph.D. · 485 employees · United States · https://www.ginkgo.bio